Patents by Inventor John Court
John Court has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7538146Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: GrantFiled: December 30, 2006Date of Patent: May 26, 2009Assignee: CIBA Vision CorporationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorge Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, Jr., Jurgen Vogt, Lynn Cook Winterton
-
Patent number: 7514448Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: April 4, 2005Date of Patent: April 7, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeremy Green, Andrew Miller, Juan-Miguel Jimenez, Craig Marhefka, Jingrong Cao, John Court, Upul Bandarage, Huai Gao, Suganthini Nanthakumar
-
Patent number: 7507826Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: March 30, 2005Date of Patent: March 24, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce
-
Patent number: 7494988Abstract: The present invention relates to compounds that are useful as protease inhibitors, particularly as serine protease inhibitors, and more particularly as hepatitis C NS3 protease inhibitors. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HCV NS3 protease activity and consequently, may be advantageously used as therapeutic agents against the hepatitis C virus and other viruses that are dependent upon a serine protease for proliferation. This invention also relates to methods for inhibiting the activity of proteases, including hepatitis C virus NS3 protease and other serine proteases, using the compounds of this invention and related compounds.Type: GrantFiled: March 19, 2003Date of Patent: February 24, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Perni, John Court, Ethan O'Malley, Govinda Rao Bhisetti
-
Publication number: 20090046242Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. In one embodiment, an opthalmic lens is a copolymerization product of at least one oxyperm, at least one ionoperm, and a crosslinker. In one embodiment, a lens has a tensile modulus of less than about 3.0 MPa, yet in another embodiment, the tensile modulus is between about 0.5 to about 1.5 MPa.Type: ApplicationFiled: October 16, 2008Publication date: February 19, 2009Applicant: CIBA VISION CORPORATIONInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorge Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, JR., Jurgen Vogt, Lynn Cook Winterton
-
Publication number: 20090039535Abstract: A method for making a silicone hydrogel contact lens is provided. In one embodiment, a prepolymer mixture is polymerized in a lens mold in an atmosphere having less than about ppm oxygen to form a silicone hydrogel contact lens suitable for extended wear as characterized by producing less than 10% corneal swelling after a period of continuous wear of 7 days including normal sleep periods. In one embodiment, the prepolymer mixture comprises at least one oxyperm material containing hydrophilic groups, wherein the at least one oxyperm material is a siloxane-containing macromer or monomer, at least one ionperm material, and a cross-linking agent. In certain embodiments, the polymerization of the prepolymer mixture may be carried out in an atmosphere having less than about 1000 ppm oxygen.Type: ApplicationFiled: October 16, 2008Publication date: February 12, 2009Applicant: CIBA Vison CorporationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorg Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, JR., Jurgen Vogt, Lynn Cook Winterton
-
Patent number: 7468398Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: GrantFiled: June 7, 2005Date of Patent: December 23, 2008Assignee: CIBA Vision CorporationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorg Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, Jr., Jurgen Vogt, Lynn Cook Winterton
-
Publication number: 20070105973Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: ApplicationFiled: December 30, 2006Publication date: May 10, 2007Applicant: CIBA Vision CorporationInventors: Paul Nicolson, Richard Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Griesser, Arthur Ho, Jens Hopken, Bronwyn Laycock, Qin Liu, Dieter Lohmann, Gordon Meijs, Eric Papaspiliotopoulos, Judy Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Terry, Jurgen Vogt, Lynn Winterton
-
Publication number: 20070105974Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: ApplicationFiled: December 30, 2006Publication date: May 10, 2007Applicant: CIBA Vision CorporationInventors: Paul Nicolson, Richard Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Griesser, Arthur Ho, Jens Hopken, Bronwyn Laycock, Qin Liu, Dieter Lohmann, Gordon Meijs, Eric Papaspiliotopoulos, Judy Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Terry, Jurgen Vogt, Lynn Winterton
-
Publication number: 20070043063Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: March 30, 2005Publication date: February 22, 2007Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang
-
Publication number: 20060003968Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: ApplicationFiled: April 4, 2005Publication date: January 5, 2006Inventors: Jeremy Green, Andrew Miller, Juan-Miguel Jimenez, Craig Marhefka, Jingrong Cao, John Court, Upul Bandarage, Huai Gao, Suganthini Nanthakumar
-
Publication number: 20050228065Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: ApplicationFiled: June 7, 2005Publication date: October 13, 2005Applicant: CIBA Vision CorporationInventors: Paul Nicolson, Richard Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Griesser, Arthur Ho, Jens Hopken, Bronwyn Laycock, Qin Liu, Dieter Lohmann, Gordon Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Terry, Jurgen Vogt, Lynn Winterton
-
Patent number: 6951894Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: GrantFiled: August 17, 2000Date of Patent: October 4, 2005Assignee: CIBA Vision CorporationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jörg Griesser, Arthur Ho, Jens Höpken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, Jr., Jürgen Vogt, Lynn Cook Winterton
-
Publication number: 20050215486Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: ApplicationFiled: February 4, 2005Publication date: September 29, 2005Inventors: Kevin Cottrell, John Court, David Deininger, Luc Farmer, Janos Pitlik
-
Publication number: 20050137139Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: ApplicationFiled: September 7, 2004Publication date: June 23, 2005Inventors: Robert Perni, John Court, Shawn Britt, Janos Pitlik, John van Drie
-
Patent number: 6899216Abstract: An escalator has steps shaped (1) to negotiate curves. The steps are suitably linked (4)(5)(6), guided (3)(10)(11), contained and powered so that the escalator can rise, fall, follow a horizontal path, be straight or curved in any predetermined sequence within the design parameters. The steps remain usable in both the flow and return paths. Shields are fitted to guard against entrapment of shoes or other apparel between the moving and stationary parts. For boarding or alighting safely, straight horizontal lengths may be included with appropriate means for passengers crossing from or to a stationary floor.Type: GrantFiled: December 5, 2001Date of Patent: May 31, 2005Assignee: Levytator LimitedInventor: John Court Levy
-
Publication number: 20040050654Abstract: An escalator has steps shaped (1) to negotiate curves. The steps are suitably linked (4)(5)(6), guided (3)(10) (11), contained and powered so that the escalator can rise, fall, follow a horizontal path, be straight or curved in any predetermined sequence within the design parameters. The steps remain usable in both the flow and return paths. Shields are fitted to guard against entrapment of shoes or other apparel between the moving and stationary parts. For boarding or alighting safely, straight horizontal lengths may be included with appropriate means for passengers crossing from or to a stationary floor.Type: ApplicationFiled: June 2, 2003Publication date: March 18, 2004Inventor: John Court Levy
-
Publication number: 20030236242Abstract: The present invention relates to compounds that are useful as protease inhibitors, particularly as serine protease inhibitors, and more particularly as hepatitis C NS3 protease inhibitors. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HCV NS3 protease activity and consequently, may be advantageously used as therapeutic agents against the hepatitis C virus and other viruses that are dependent upon a serine protease for proliferation. This invention also relates to methods for inhibiting the activity of proteases, including hepatitis C virus NS3 protease and other serine proteases, using the compounds of this invention and related compounds.Type: ApplicationFiled: March 19, 2003Publication date: December 25, 2003Inventors: Robert Perni, John Court, Ethan O'Malley, Govinda Rao Bhisetti
-
Patent number: 5965631Abstract: An ophthalmic lens suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: GrantFiled: July 1, 1998Date of Patent: October 12, 1999Assignees: CIBA Vision Corporation, Commonwealth Scientific and Industrial Research OrganisationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorg Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, Jr., Jurgen Vogt, Lynn Cook Winterton
-
Patent number: 5849811Abstract: An ophthalmic lens suited for extended-wear for periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange occurs between the lens and the eye. A preferred lens is a copolymerization product of a oxyperm macromer and an ionoperm monomer. The invention encompasses extended wear contact lenses, which include a core having oxygen transmission and ion transmission pathways extending from the inner surface to the outer surface.Type: GrantFiled: July 17, 1996Date of Patent: December 15, 1998Assignees: CIBA Vision Corporation, The Commonwealth of Australia Commonwealth Scientific and Industrial Research OrganizationInventors: Paul Clement Nicolson, Richard Carlton Baron, Peter Chabrecek, John Court, Angelika Domschke, Hans Jorg Griesser, Arthur Ho, Jens Hopken, Bronwyn Glenice Laycock, Qin Liu, Dieter Lohmann, Gordon Francis Meijs, Eric Papaspiliotopoulos, Judy Smith Riffle, Klaus Schindhelm, Deborah Sweeney, Wilson Leonard Terry, Jr., Jurgen Vogt, Lynn Cook Winterton